Neuronetics Gains Breakthrough as New York Medicaid Expands Coverage for TMS Depression Therapy

Neuronetics Gains Breakthrough as New York Medicaid Expands Coverage for TMS Depression Therapy

MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) announced Wednesday that New York State Medicaid will begin covering transcranial magnetic stimulation (TMS) for adults with major depressive disorder (MDD), a move expected to expand access to thousands of patients who have not responded to traditional treatments. Coverage will take effect October 1, 2025, for fee-for-service Medicaid members and November 1, 2025, for those enrolled in Medicaid Man…